Stifel Reiterates Buy Rating on Rani Therapeutics Holdsing s (RANI)
Tweet Send to a Friend
Stifel analyst Annabel Samimy reiterated a Buy rating and $8.00 price target on Rani Therapeutics Holdings (NASDAQ: RANI).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
